Literature DB >> 2521814

Immunomodulatory and therapeutic properties of FK-565 in mice.

J E Talmadge1, B Lenz, M Schneider, H Phillips, C Long.   

Abstract

The heptanoyl tripeptide, FK-565 is a biological response modifier with potent therapeutic properties for the treatment of experimental and spontaneous metastases. Doses of FK-565 greater than 5 mg/kg are required for in vivo augmentation of natural killer cells, macrophages, and for therapeutic activity, presumably because FK-565 is a peptide small molecular mass which is rapidly degraded and excreted. Optimal therapeutic activity is observed at approximately 25-50 mg/kg FK-565, administered i.v. three times per week for 4 weeks. In addition to its therapeutic properties, which were consistently greater than the positive control at optimal doses, FK-565 had significant immunoaugmentary properties for natural killer cells, macrophages, and T cells both in vitro and in vivo, suggesting that its therapeutic activity is due to immune augmentation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521814     DOI: 10.1007/bf00199108

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  A transplantable mast-cell neoplasm in the mouse.

Authors:  T B DUNN; M POTTER
Journal:  J Natl Cancer Inst       Date:  1957-04       Impact factor: 13.506

2.  Synthesis and adjuvant activity of FK-156 analogues: acyl derivatives of N-[N2-(L-alanyl-gamma-D-glutamyl)-2(L),2'(D)-diamino-1-pimeloyl ]glycine.

Authors:  S Okada; H Takeno; K Hemmi; Y Kitaura; M Hashimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-02       Impact factor: 1.645

3.  Studies on a new immunoactive peptide, FK-156. I. Taxonomy of the producing strains.

Authors:  T Gotoh; K Nakahara; M Iwami; H Aoki; H Imanaka
Journal:  J Antibiot (Tokyo)       Date:  1982-10       Impact factor: 2.649

4.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

5.  Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes.

Authors:  N Weissmann; G Leyhausen; A Maidhof; W Tanaka; H Umezawa; W E Müller
Journal:  J Antibiot (Tokyo)       Date:  1985-06       Impact factor: 2.649

6.  Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state.

Authors:  S Sone; S Mutsuura; M Ogawara; T Utsugi; E Tsubura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose.

Authors:  J E Talmadge; J Adams; H Phillips; M Collins; B Lenz; M Schneider; E Schlick; R Ruffmann; R H Wiltrout; M A Chirigos
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

8.  Central pyrogenic activity of muramyl dipeptide.

Authors:  G Riveau; K Masek; M Parant; L Chedid
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

9.  Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide.

Authors:  M Parant; G Riveau; F Parant; C A Dinarello; S M Wolff; L Chedid
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

10.  Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s).

Authors:  I Gery; B H Waksman
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.